• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy
ConclusionsIn this pilot study of 50 patients, low-dose apixaban was safe and well tolerated as thromboprophylaxis for patients with MM receiving IMiDs. No patients experienced VTE, major hemorrhage, stroke, or MI. Further randomized studies are needed to validate apixaban as a standard primary prevention anti-thrombotic strategy for patients with MM receiving IMiDs.DisclosuresMoslehi: Bristol-Myers Squibb: Consultancy, Research Funding. Jagasia: Incyte Corporation: Membership on an entity's Board of Directors or advisory committees.
Source: Blood - November 21, 2018 Category: Hematology Authors: Cornell, R. F., Goldhaber, S. Z., Engelhardt, B. G., Moslehi, J., Jagasia, M., Patton, D., Harrell, S. L., Hall, R. L., Wyatt, H., Piazza, G. Tags: 332. Antithrombotic Therapy: Poster I Source Type: research

Central Nervous System Complications and Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation
This retrospective study of 351 patients, who have undergone allogeneic hematopoietic stem cell transplantation between 2002 and 2011 at the University of Nebraska Medical Center, demonstrated 12% incidence of central nervous system complications. The most common complications included posterior reversible encephalopathy syndrome (40%), stroke or transient ischemic attack (24%), seizures (20%), and infection (9%). The 5-year overall survival was significantly lower among patients with versus without central nervous system complications (14% vs. 44%, p=0.0004).
Source: Clinical Lymphoma, Myeloma and Leukemia - June 18, 2015 Category: Hematology Authors: Vijaya Raj Bhatt, Vamshi Balasetti, Jagar J. Abduall, Smith Giri, James O. Armitage, Fausto R. Loberiza, R. Gregory Bociek, Philip J. Bierman, Lori J. Maness, Julie M. Vose, Pierre Fayad, Mojtaba Akhtari Source Type: research

Changing Incidence of Major Cardiovascular Events in Multiple Myeloma Patients over Time
Conclusion: CVD is a common complication in MM patients: within 5 years of a MM diagnosis, over 25% develop CVD requiring hospitalization. Contrary to our hypothesis, we did not find increased CVD admissions in the most recent era. Decreased admissions due to CHF and CAD in the most recent era of diagnosis may indicate a greater awareness of this issue, routine thromboprophylaxis with anti-platelet agents in patients being treated with immunomodulatory agents, or changes in secular trends in the diagnosis and treatment of CVD. CVD is an ongoing source of morbidity for MM patients requiring further study and the vigilance o...
Source: Blood - November 21, 2018 Category: Hematology Authors: Rosenberg, A. S., Li, Q., Brunson, A. M., Tuscano, J., Wun, T., Keegan, T. H. M. Tags: 904. Outcomes Research-Malignant Conditions: Poster II Source Type: research

Current status of drug repositioning in hematology
Expert Rev Hematol. 2021 Oct 16. doi: 10.1080/17474086.2021.1995348. Online ahead of print.ABSTRACTINTRODUCTION: Drug repositioning (DR) is defined as determining new therapeutic applications for existing drugs. This approach is advantageous over de novo drug discovery in accelerating clinical development, in terms of lower costs, a shortened development period, a well-known action mechanism, a feasible dosage, and an acceptable safety profile.AREAS COVERED: This work was aimed at reviewing agents with successful DR in hematology.EXPERT OPINION: Thalidomide and plerixafor have been successfully repositioned for treating mu...
Source: Expert Review of Hematology - October 18, 2021 Category: Hematology Authors: Akihiro Ohmoto Shigeo Fuji Source Type: research